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Utility of Blood Cellular Indices in the Risk
Stratiﬁcation of Patients Presenting with
Acute Pulmonary Embolism
Brett Slajus, MPH1 , Yevgeniy Brailovsky, DO2 , Iman Darwish, BS1
Jawed Fareed, PhD, FAHA3 , and Amir Darki, MD, MSc1

,

Abstract
Pulmonary embolism (PE) clinical manifestations vary widely, and that scope is not fully captured by current all-cause mortality
risk models. PE is associated with inﬂammatory, coagulation, and hemostatic imbalances so blood cellular indices may be prognostically useful. Complete blood count (CBC) data may improve current risk models like the simpliﬁed pulmonary embolism
severity index (sPESI) for all-cause mortality, offering greater accuracy and analytic ability. Acute PE patients (n = 228) with conﬁrmatory diagnostic imaging were followed for all-cause mortality. Blood cellular indices were assessed for association to allcause mortality and were supplemented into sPESI using multivariate logistic regression. Multiple blood cellular indices were
found to be signiﬁcantly associated with all-cause mortality in acute PE. sPESI including red cell distribution width, hematocrit
and neutrophil-lymphocyte ratio had better predictive ability as compared to sPESI alone (AUC: 0.852 vs 0.754). Blood cellular
indices contribute an inﬂammatory and hemodynamic perspective not currently included in sPESI. CBC with differential is a
widely used, low-cost test that can augment current risk stratiﬁcation tools for all-cause mortality in acute PE patients.
Keywords
pulmonary embolism, sPESI, complete blood count, inﬂammation, covid-19

Introduction
Pulmonary embolism (PE) is a life-threatening condition with
variable severity that results from dysregulation of complex
inﬂammatory and hematologic processes. In the United
States, the incidence of acute PE is estimated to be 600,000
cases annually.1 Acute PE is the third leading causing of cardiovascular death in the United States, accounting for over 100,000
deaths annually.1 Additionally, there is higher incidence among
those with advancing age as well as among African Americans
and Caucasians as compared to other races and ethnicities.1
Within acute PE manifestations, there is signiﬁcant variability
in severity as well as mortality risk.2,3 Short-term all-cause mortality rates differ widely, from 2% among low-risk normotensive patients to 95% among those experiencing cardiac arrest.2
Due to the wide symptom proﬁle at presentation, acute PE
are stratiﬁed by symptom severity and hemodynamic stability.3
Diagnosis is primarily made using a combination of clinical
assessment and conﬁrmatory imaging with supplementary
tools like simpliﬁed Geneva and Wells scoring systems to
assist with pre-test probability.4,5 Subsequent testing includes
echocardiography, six-minute walk test, and laboratory testing

to further evaluate cardiopulmonary functioning of patients
and aid in treatment algorithms.3,6,7 In terms of prognostic
risk, most commonly the Pulmonary Embolism Severity
Index (PESI) and its simpliﬁed version (sPESI) are used to stratify patients by risk of mortality and are adept at identifying
low-risk patients suitable for outpatient management.2,8,9
However, these models have suboptimal accuracy for higher
risk patients due to low speciﬁcity, and additional testing can
be time and resource dependent as well as costly for patients.3,9
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Conversely, complete blood count with differential testing is
a cost-effective and routinely obtained lab test used throughout
the clinical course of patients.10 Complete blood counts parameters, or blood cellular indices, often are obtained daily during a
hospital stay. There is growing literature demonstrating the
utility of individual blood cellular indices obtained from complete blood counts in predicting PE patient prognosis.11–15
Venous thromboembolisms occur in part due to complex
inﬂammatory and coagulation processes associated with platelet activation and inﬂammatory cascades.16,17 There are
increased levels of pro-inﬂammatory cytokines as well as
evolving ratios of immune cells interacting with the thrombus
itself.18,19 Various diseases like malignancy, infection, and systemic lupus erythematous associated with acute PE also have
hematologic and immunologic abnormalities.17 Complete
blood count with differential includes a broad scope of blood
cellular indices and a perspective not captured in existing risk
models which relies on clinical history and exam ﬁndings.2,8
The primary objective of our study is to determine any associations between blood cellular indices and all-cause mortality.
Since PE reﬂects inﬂammatory and coagulation imbalances, we
hypothesize there will be abnormal ﬁndings that suggest
Table 1. Baseline Demographics, Co-Morbidities, Vital Signs of Living
and Deceased Patients with Acute PE.
Living (n = 180)
Age (median ±
IQR)
Female, n (%)
CAD, n (%)
CHF, n (%)
T2DM, n (%)
HTN, n (%)
CPD, n (%)
COPD, n (%)
Prior DVT, n (%)
Prior PE, n (%)
Prior Stroke, n (%)
PE severity
Low-risk, n (%)
Submassive, n
(%)
Massive, n (%)
Vitals
SBP (mmHg)
(median ± IQR)
HR (beats/min)
(median ± IQR)
RR (breaths/min)
(median ± IQR)
O2 Saturation
(%) (median ±
IQR)

62 (52.0–70.5)

Deceased (n = 48)

P-value

65.0 (55.0–73.0)

0.13

90 (50%)
19 (10.6%)
19 (10.6%)
40 (22.2%)
97 (53.9%)
9 (5.0%)
7 (3.90%)
22 (12.2%)
21 (11.7%)
14 (7.8%)

27 (56.3%)
8 (16.7%)
9 (18.8%)
12 (25.0%)
26 (54.2%)
6 (12.5%)
5 (10.4%)
14 (29.2%)
11 (22.9%)
5 (10.4%)

0.42
0.26
0.14
0.83
0.89
0.10*
0.14*
<0.01
0.05
0.57

60 (33.3%)
109 (60.6%)

13 (27.1%)
29 (60.4%)

0.28

11 (6.10%)

6 (12.5%)

107 (97–118)

100.5 (88–109.8)

102 (90–114)

118.5 (94.5–135.5)

<0.01

23.5 (20–26.3)

23.5 (20.0–35.0)

0.36

93 (90–95)

90 (85–92)

0.03

<0.01

Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; CPD, chronic pulmonary
disease; DVT, deep vein thrombosis; HR, heart rate; HTN, hypertension; PE,
pulmonary embolism; RR, respiratory rate; SBP, systolic blood pressure; T2DM,
type 2 diabetes mellitus.

increased risk of all-cause mortality. Our study also sought to
assess the predictive ability of complete blood count data for
all-cause mortality. As such, a secondary objective was to supplement the current sPESI model with additional blood cellular
indices to improve predictive skill of the model. Supplementary
parameters to sPESI may boost its prognostic abilities and be
useful in accurately identifying high-risk patients.

Material and Methods
Patient Selection and Data Collection
Patients 18 years or older who were diagnosed with and treated
for with acute PE between March 2016 and June 2019 at Loyola
University Medical Center were prospectively recruited by the
PE response team (PERT). Diagnosis was made using CT angiography or ventilation perfusion (VQ) scan conﬁrmed by PERT
team. PE severity was classiﬁed as low risk, submassive, and
massive set forth by guidelines from the American College of
Cardiology and American Heart Association.3 Baseline demographics were retrospectively collected using the EMR.
Complete blood counts with differentials were collected on
patients throughout their hospital course as a part of routine
care and were also collected retrospectively from the EMR,
using samples obtained within 24 hours of PE diagnosis prior
to treatment.
Patients were excluded from the study due to presence of
infection, chronic inﬂammatory condition, or ongoing cancer
treatment at time of PE diagnosis. Patients who were missing
complete blood count with differential results, were undergoing
chemotherapy for cancer treatment, or were on immunosuppressants were excluded from the study as well. If a patient
had multiple acute PEs during study period, only the ﬁrst
instance was included in the study analysis. Patients were subsequently followed for all-cause mortality using the EMR until
completion of the study in July 2019.

Statistical Analysis
Descriptive statistics were divided by mortality and reported as
median and interquartile range for nonparametric variables,
mean and standard deviation for parametric variables, and as
percentage for categorical variables. Continuous variable distributions were checked using Kolmogorov-Smirnov testing.
Statistical signiﬁcance was analyzed for continuous variables
using two-sample t-test, Mann Whitney nonparametric test
while categorical variables were analyzed using Pearson’s
chi-square and Fisher’s exact test. P values were two-sided
and values <0.05 were considered statistically signiﬁcant.
PLR was calculated as the ratio of platelets to lymphocytes,
NLR as the ratio of neutrophils to lymphocytes, PNR as the
ratio of platelets to neutrophils, and LMR as the ratio of lymphocytes to monocytes.
Receiver operator curves were created to determine optimal
cutoff values using Youden J index to predict all-cause mortality. Univariate and multivariate binary logistic regression were
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performed to identify independent predictors of all-cause mortality. Forward multivariate logistic regression was used to
develop a composite sPESI risk prediction model with supplemental parameters. Variables were sequentially added to the
multivariate model in order of greatest area under the curve
(AUC). For the composite sPESI model including blood cellular indices, one point was added for every additional condition
met beyond the original sPESI model. sPESI and the composite
sPESI were then compared using ROC curves and optimal
cutoffs were determined. Statistical analysis was performed
using IBM SPSS Statistics for Windows, Version 25.0
(Armonk, NY, IBM Corp).

Results
There were 383 consecutive patients enrolled in the study with
228 patients included for analysis after exclusion criteria was
applied. Of the patients analyzed, 180 (79%) were survivors
with 48 (21%) non-survivors at the end of the study period
(Table 1). Patients were followed for a median of 56 days
(IQR=17-182) from time of PE diagnosis to end of study or
mortality. Of the 48 deceased patients, 7 (14.6%) deaths were
related to PE, 26 (54.2%) were related to non-PE causes such
as hospice care, metastatic cancer, or septic shock at a later
time point, and 15 (31.2%) were due to unknown causes.
Based on PE severity, 73 (32%) of patients were deﬁned as
low risk, 138 (60.5%) as submassive, and 17 (7.5%) as massive.
Table 2. PESI Scores and Laboratory Parameters by All-cause
Mortality in Patients with Acute PE.
Living (n = 180)
(median ± IQR)
PESI score

91 (69.3–124)

sPESI score
WBC (K/µL)
Neutrophil Count (K/
mm3)
Lymphocyte Count (K/
mm3)
Eosinophil Count (K/
mm3)
Basophil Count (K/
mm3)
Monocyte Count (K/
mm3)
HCT (%)a
HGB (g/dL)
MPV (Fl)
RDW (%)
Platelet Count (K/µL)

Deceased
(n = 48)
(median ± IQR) P-value
<0.01

There were higher mortality rates with increasing PE severity
from low-risk (17.8%), submassive (21.0%) and massive
(35.5%), which did not reach statistical signiﬁcance.
Decreased systolic blood pressure (100.5 vs 107 mmHg;
p=0.03) and oxygen saturation (90 vs 93; p<0.01), as well as
elevated heart rate (118.5 vs 102; p<0.01) were associated
with all-cause mortality. There were no other signiﬁcant differences between mortality groups for demographic data or past
medical history.
As seen in Table 2, deceased patients were more likely to
have both a higher PESI (131.5 vs 91.0; p<0.01) and sPESI
score (2.0 vs 1.0; p<0.01). Red cell distribution width
(RDW), PLR, and NLR were elevated in deceased patients
while hematocrit, hemoglobin, lymphocyte count, eosinophil
count, and LMR were lower in deceased patients (all p<0.01).
White blood cell count was higher in deceased patients, while
platelet count was lower, but neither was signiﬁcantly different
from alive patients or outside clinical reference value ranges.
ROC curves depicting the predictive value of blood cellular
indices to predict all-cause mortality are demonstrated in
Figure 1. The Youden J index derived cutoff value of RDW
was ≥15.15, hematocrit was ≤34.15, hemoglobin ≤11.15,
NLR ≥5.50, PLR ≥256.70, eosinophil count ≤0.06, LMR
≤1.61. RDW was shown to have the highest predictive value
with an AUC of 0.776, followed by hemoglobin (0.741), hematocrit (0.737), NLR (0.688), eosinophil count (0.664), LMR
(0.664), and PLR (0.659). Parameter cutoff value sensitivity
and speciﬁcity are demonstrated in Table 3.
The ﬁnal multivariate model included sPESI (p<0.01) and
independent predictors RDW (p<0.01), hematocrit (p=0.02) and
NLR (p<0.01) as seen in Table 4. The addition of hemoglobin,
eosinophil count, PLR, LMR were not found to be independent
predictors of all-cause mortality and did not improve the composite model further. Illustrated in Figure 2, the composite model of
cellular indices and sPESI offered improved predictive ability
(AUC 0.852, 95% CI: 0.791-0.912) as compared to sPESI alone
(AUC 0.754, 95%CI: 0.678-0.829) both with a cutoff value of
≥2. The speciﬁcity of the composite model improves as compared
to sPESI alone (81.0% vs 64.2%); however, sensitivity was
slightly lower (70.8% vs 72.9%). Positive and negative predictive
value of the composite model was 50% and 91.3%, respectively,
while 35.4% and 89.9% for sPESI alone.

1.0 (0.0–2.0)
9.2 (7.0–11.2)
6.3 (4.73–8.5)

131.5 (107–
185)
2.0 (1.0–4.0)
9.4 (6.0–11.7)
6.7 (4.1–9.6)

<0.01
0.77
0.95

1.5 (1.1–2.2)

0.9 (0.6–1.3)

<0.01

0.1 (0.1–0.2)

0.0 (0.0–0.1)

<0.01

0.0 (0.0–0.1)

0.0 (0.0–0.1)

0.91

Discussion

0.7 (0.5–0.9)

0.6 (0.4–0.9)

0.13

39.5 ± 6.5
13.3 (11.7–14.7)
8.3 (7.7–9.0)
14.2 (13.4–15.7)
226.5 (175–282)

33.7 ± 6.8
10.8 (9.5–12.5)
8.3 (7.4–8.8)
16.5 (15.4–19)
214 (126–
297.3)

<0.01
<0.01
0.19
<0.01
0.43

Risk prediction models like PESI2 and sPESI8 score are presently used to assess both disease severity and prognosis for
PE to optimize patient care. Current PE mortality prediction
models make use of medical history and signs of hemodynamic
stability only.2,3,8 These models can be further enriched with
routine laboratory data. With a high negative predictive value
and low positive predictive value, sPESI is primarily useful in
ﬁnding low risk patients.9,20 Due to lower accuracy, further
testing such as echocardiography and six-minute walk test is
often needed to supplement established decision-making tools
for intermediate and high risk patients.6,7,21 The use of routinely

Abbreviations: HCT, hematocrit; HGB, hemoglobin; MPV, mean platelet
volume; PESI, pulmonary embolism severity index; RDW, red blood cell
distribution width; sPESI, simpliﬁed pulmonary embolism severity index.
a
Analysis reported as mean ± standard deviation.
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Figure 1. Predictive value of individual blood cellular indices on all-cause mortality in patients with acute PE. Abbreviations: RDW, red blood
cell distribution width; HCT, hematocrit; HGB, hemoglobin; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR,
lymphocyte to monocyte ratio; PNR, platelet to neutrophil ratio.

collected laboratory data in risk stratifying patients could help
reduce time and resources when working up PE patients. PE
pathophysiology reﬂects dysregulation of coagulation, inﬂammatory and hematologic processes.17,18,22 There is growing evidence of laboratory parameters predictive of all-cause mortality,
including MPV,14,23,24 blood cellular ratios,12,13,23,25 RDW,15
and anemia,11 few studies have incorporated multiple

parameters into existing risk prediction models. It is necessary
to further explore using blood cellular indices to predict allcause mortality to improve current PE treatment algorithms.
Our study found that sPESI could be further optimized for
predicting all-cause mortality with the addition of routine laboratory blood cellular indices. Within our patient cohort, the individual parameter with greatest predictive ability was red cell
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Table 3. Individual Parameter ROC Area Under the Curve (AUC),
Optimal Youden J Index Cut-off Values, Sensitivity and Speciﬁcity for
Predicting All-cause Mortality Among PE Patients.
AUC
(95% CI)
RDW
HCT
HgB
NLR
PLR
Eosinophil Count
LMR
sPESI alone
sPESI + RDW +
HCT + NLR

0.776
0.737
0.741
0.688
0.659
0.668
0.664
0.754
0.852

Cutoff
Value
≥15.15
≤34.15
≤11.15
≥5.50
≥256.70
≤0.06
≤1.61
≥2.00
≥2.00

Sensitivity

Speciﬁcity

0.792
0.583
0.583
0.667
0.542
0.558
0.667
0.729
0.708

0.698
0.833
0.828
0.683
0.856
0.785
0.708
0.642
0.810

Abbreviations: HCT, hematocrit; HGB, hemoglobin; LMR, lymphocyte to
monocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to
lymphocyte ratio; RDW, red blood cell distribution width; sPESI, simpliﬁed
pulmonary embolism severity index.

distribution width, which was found to be an independent predictor beyond sPESI and other cellular markers. It has been
found previously that elevated RDW is a strong prognostic
symbol of mortality in hospital admissions.26 RDW was strongest at predicting cardiovascular disease mortality but was also
elevated in other disease states.26 Anisocytosis has been found
in the context of VTE with strong diagnostic value for risk
assessment27 as well as in predicting all-cause mortality in PE
patients.15 Though the underlying pathophysiology of why anisocytosis occurs in PE remains unclear, its presence as a general
manifestation of chronic disease and inﬂammation is apparent.
Despite elevated RDW being nonspeciﬁc and present in numerous disease states, its predictive ability was better than sPESI
alone within our study and contributed to the improved accuracy of the composite sPESI model.
Previously, our group reported PLR and NLR were signiﬁcantly associated with all-cause mortality in PE patients and
could supplement sPESI,25 which was in conjunction with
other studies.12,13,23 At present, we found elevated ratios of
PLR, NLR along with decreased LMR and lymphocyte count
associated with all-cause mortality. Other studies have found
increased neutrophil count12,13,23 or decreased monocyte
count,23 but our study did not ﬁnd any signiﬁcant association
Table 4. Forward logistic Regression of Blood Cellular Indices to
Supplement sPESI Predictive Model.
Cutoff value
sPESI
RDW
HCT
NLR

–
≥15.15
≤34.15
≥5.50

Multivariate analysis
OR (95% CI)

P-value

1.84 (1.31-2.58)
4.92 (2.0-12.12)
2.67 (1.15-6.19)
3.90 (1.72-8.83)

<0.01
<0.01
0.02
<0.01

Abbreviations: HCT, hematocrit; NLR, neutrophil to lymphocyte ratio; RDW,
red blood cell distribution width; sPESI, simpliﬁed pulmonary embolism severity
index.

with all-cause mortality for these blood cellular indices. There
are changes in various inﬂammatory cell amounts during thrombus development and resolution.19 If studies are capturing different timepoints within the PE course it may reﬂect
variability in cellular markers though this must be studied
further. It may be that lymphocyte count is a key component
to these cellular ratios, but more likely the ratios reﬂect the
necessity of using multiple cell counts to obtain a comprehensive assessment of inﬂammatory processes. As our study
shows, there is some overlap in predictiveness of some cellular
ratios, but the inclusion of NLR was found to be an independent
predictor and a beneﬁcial inclusion to sPESI.
Laboratory signs of anemia, speciﬁcally low hemoglobin and
hematocrit were also found to predict all-cause mortality in acute
PE. In a study by Jimenez et al, lower hemoglobin ranges were
associated with higher rates of mortality in PE patients regardless
of gender.11 Our study found similar cutoffs of <34.15 g/dl for
hematocrit and <11.15 g/dl for hemoglobin associated with
increased risk of mortality. Both hematocrit and hemoglobin
were found to be independently predictive in addition to sPESI,
but only hematocrit was included in the ﬁnal model to avoid
redundancy. Anemia may serve as a prognostic marker of worsening renal function or presence of chronic disease that can cause
disturbances to erythropoiesis.28
Our study demonstrated the utility of complete blood count
data to supplement sPESI, but it is important to explore additional
parameters. Other studies found elevated MPV useful in diagnosis
of acute PE24 as well as predictive of all-cause mortality.14,23
Increased MPV has been associated with platelet activation and
adhesion which occur in acute PE.29 In contrast, our study did
not ﬁnd a signiﬁcant difference in MPV, and interestingly the
same median value between living and deceased patients. The
incongruous ﬁndings may be due to our study obtaining complete
blood count data within a 24-hour period prior to PE diagnosis,
which may be prior to platelet changes that result in increased
MPV. Another interesting ﬁnding was the association of elevated
eosinophil count with all-cause mortality, though it was not
included in the ﬁnal model. Two case studies were published
on patients with eosinophilic disorders with PE suggesting a possible correlation.29,30 Further research is necessary to demonstrate
a more comprehensive association between eosinophilia and PE
mortality, with greater granularity of cell counts. Elevations in
both pro-inﬂammatory and anti-inﬂammatory cytokines, including IL-4, IL-6, IL-8, IL-10, VEGF, IFN-λ, TNF-α, IL-1α,
IL-1β, MCP-1 and EGF, have also been associated with increased
PE severity.31 Like cellular markers, many cytokines likely are
elevated in PE due to an enhanced systemic inﬂammatory
response. It is important to assess the utility of these inﬂammatory
markers with clinical outcomes as it may provide an additional
perspective not currently encompassed in PE risk prediction
models or by cellular indices.
Despite the inclusion of malignancy in sPESI and PESI, often
there is an altered hematologic proﬁle, especially in the setting of
hematologic malignancy. For this reason, patients with co-morbid
cancer were excluded from the study due to the presumed confounding effects on complete blood count data. Future studies
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Figure 2. Comparing predictive value of sPESI and composite sPESI for all-cause mortality in acute PE patients. Abbreviations: sPESI, simpliﬁed
pulmonary embolism severity index; RDW, red blood cell distribution width; HCT, hematocrit; NLR, neutrophil to lymphocyte ratio.

are necessary to elucidate the predictive value of blood cellular
indices in a more comprehensive patient cohort, as laboratory
data and malignancy may capture similar predictive data.
Infected and septic patients were equally excluded for presumed
confounding effects to hematologic and inﬂammatory markers.
The inclusion of blood cellular indices may provide greater opportunities to demonstrate mortality risk factors and dysregulation
that can predispose patients. Our study was able to illustrate the
utility of RDW, NLR, and hematocrit in patients lacking
cancer, which suggests multiple disease states including PE
itself can contribute to hematologic and inﬂammatory imbalances.
Further research is required to deduce the predictive abilities of
blood cellular indices in malignancy, infection and rheumatologic
diseases. Within these patient populations it may be that blood
cellular indices offer additional information sPESI alone does
not provide, which may help in identifying high risk patients
who require more substantive therapy.
Further research is necessary to determine the best predictive model for PE, making use of additional routinely used
clinical tools like laboratory data, echocardiography, and sixminute walk test. As this study purports, complete blood
count information can augment current PE risk models.
Echocardiography6 and six-minute walk test7 offer an assessment of cardiopulmonary functioning used in clinical decision making that also may be useful in risk stratifying
patients by mortality. Likewise, further development of biochiop array technology would offer an efﬁcient way to
rapidly assess multiple inﬂammatory markers associated
with greater PE severity like IL-6, EGF, and IL-8 not currently available to most clinical settings.31 Though sPESI

includes comorbidities and vital signs as potential risk
factors, it does not offer a more comprehensive evaluation
of the effects of an acute PE on the patient.8 In patients
with diminished ventricular or exercise performance, it
may suggest poor prognosis but there is limited data assessing their long-term prognostic ability. Furthermore, there
may be inter-operator variability in performing these labor
and time-intensive tests as compared to the relatively standardized process of obtaining laboratory data. Other laboratory markers such as troponin and BNP have been found to
be elevated in acute PE and associated with short term allcause mortality.21,32,33 Santos et al found elevated troponin
and BNP cardiac biomarkers to indicate worsened prognosis
in patients with intermediate-high risk.33 There is an abundance of testing options available to risk stratify patients, it
is important for future studies to weigh the beneﬁts of each
and integrate these results into a comprehensive risk model.
One of the primary strengths of these blood cellular indices
is the affordability and accessibility of obtaining complete
blood counts. Complete blood counts often are collected daily
throughout a patient’s hospital stay and can also be obtained
in the emergency department. Our study attempted to control
the impact of PE treatment protocols on all-cause mortality
by using blood cellular metrics obtained within 24 hours prior
to PE diagnosis. Due to the evolving cellular and inﬂammatory
nature of a thrombus, it may be worthwhile to assess laboratory
data at multiple time points.19 Not only could blood cellular
data at a future time point potentially predict mortality risk,
but stronger predictive ability may be elucidated by looking
at laboratory responsiveness to treatments.
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Study Limitations
Being an observational cohort study, the results should not be
used deﬁnitively for clinical decision making or risk prediction
without further research. As this study was performed at a tertiary care center, there may be overrepresentation of higher
acuity PE patients transferred from outside hospitals which
could bias the results toward PE patients with increased risk
factors and greater degree of laboratory abnormalities.
Conversely, since complete blood count data was taken
within a 24-hour period prior to PE diagnosis, it is possible
some were obtained prior to symptom onset and that could
serve as a potential source of variability and confounding.
The results included in this study were based on data obtained
prior to the covid-19 pandemic and before the introduction of
vaccination. Recent reports have suggested increased prevalence of PE in covid-19 patients and there is some indication
of thromboembolic complications after vaccination. In terms
of statistical analysis, the multivariate logistic regression may
reﬂect overestimates of odds ratio and signiﬁcance due to the
limitations in number of cases and limited power. The sPESI
model is validated for predicting 30-days mortality, however,
our study followed patients for a longer duration which could
impact the accuracy of sPESI and the utility of our ﬁndings.
Such factors need to be taken into account in future studies to
validate the results presented in this manuscript.

Conclusions
The primary goal of the study was to assess if complete blood
count data was associated and predictive of all-cause mortality.
We found multiple blood cellular indices to be signiﬁcantly
related, including RDW, NLR, and HCT among others.
Additionally, our secondary objective was to supplement
current risk prediction model sPESI for improved accuracy,
which we did through the inclusion of RDW, NLR and HCT.
sPESI alone has poor positive predictive value which limits
its utility in high-risk patients, our composite model PPV was
50% compared to 35.4% with sPESI alone and offered
similar NPV at 91.3% for the composite model and 89.9% for
sPESI alone. Complete blood count data is routinely obtained
in emergency and inpatient settings. It is a widely used,
low-cost, convenient laboratory test that offers an abundance
of metrics that can be incorporated within sPESI to improve
the model’s predictive ability for predicting PE risk mortality.
Future studies exploring complete blood count data further, in
addition to echocardiogram, six-minute walk test and other labbased testing may be beneﬁcial in improving current decisionmaking tools.
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